Graft Versus Host Disease Pipeline

Jul 04, 2025

The GvHD drugs treatment landscape is undergoing a dynamic transformation, driven by a wave of innovation aimed at improving patient outcomes and quality of life. Once dominated by steroids and broad immunosuppressants, the field is now witnessing a surge in targeted therapies, cellular approaches, and novel biolog...

Oct 18, 2019

Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refractory acute graft-versus-host disease (GvHD). Graft versus host disease (GvHD), as defined by the National Cancer Institu...